Connor, Clark & Lunn Investment Management (CC&L)
CASI

Connor, Clark & Lunn Investment Management (CC&L)’s CASI Pharmaceuticals CASI Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,761
Closed -$22K – 1049
2021
Q4 		$22K Sell
2,761
-3,329
-55% -$33.1K ﹤0.01% 1056
2021
Q3 		$72K Buy
+6,090
New +$82.4K ﹤0.01% 1000

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CASI Position: Q1 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of CASI Pharmaceuticals (CASI) in Q1 2022, closing a stake of 2,761 shares — an estimated $22K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CASI in Q3 2021 and held it in 2 quarters. The position peaked at $72K in Q3 2021. 44 funds tracked by Wall St. Rank hold CASI as of Q1 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining CASI Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 2,761 CASI Pharmaceuticals shares in Q1 2022, an estimated $22K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CASI Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s CASI Pharmaceuticals position peaked at $72K in Q3 2021.
  • 44 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2022, filed 12 May 2022.